Neil P. Shah

14.7k total citations · 3 hit papers
181 papers, 7.7k citations indexed

About

Neil P. Shah is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Neil P. Shah has authored 181 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Hematology, 124 papers in Genetics and 32 papers in Rheumatology. Recurrent topics in Neil P. Shah's work include Chronic Myeloid Leukemia Treatments (143 papers), Chronic Lymphocytic Leukemia Research (115 papers) and Acute Myeloid Leukemia Research (37 papers). Neil P. Shah is often cited by papers focused on Chronic Myeloid Leukemia Treatments (143 papers), Chronic Lymphocytic Leukemia Research (115 papers) and Acute Myeloid Leukemia Research (37 papers). Neil P. Shah collaborates with scholars based in United States, Germany and Italy. Neil P. Shah's co-authors include Charles L. Sawyers, Francis Y. Lee, Ping Chen, Derek Norris, Chris Tran, Catherine C. Smith, Susan Branford, Timothy P. Hughes, Irvin S. Y. Chen and Franziska Michor and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Neil P. Shah

177 papers receiving 7.5k citations

Hit Papers

Overriding Imatinib Resistance with a Novel ABL Kinase In... 2004 2026 2011 2018 2004 2005 2012 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
    2004 1.4k citations Neil P. Shah et al. profile →
  2. Dynamics of chronic myeloid leukaemia
    2005 592 citations Neil P. Shah et al. profile →
  3. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
    2012 542 citations Catherine C. Smith, Chen-Shan Chin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neil P. Shah United States 38 4.7k 3.3k 2.4k 1.8k 1.2k 181 7.7k
José M. Trujillo United States 40 3.6k 0.8× 1.7k 0.5× 2.1k 0.9× 554 0.3× 1.4k 1.1× 159 6.5k
Maryalice Stetler‐Stevenson United States 57 2.2k 0.5× 3.3k 1.0× 4.3k 1.8× 112 0.1× 8.9k 7.3× 230 15.8k
Herbert Lazarus United States 27 644 0.1× 716 0.2× 2.0k 0.8× 250 0.1× 918 0.7× 62 5.1k
Mariusz A. Wasik United States 55 1.1k 0.2× 1.1k 0.3× 3.2k 1.3× 314 0.2× 4.9k 4.0× 187 10.4k
Freda K. Stevenson United Kingdom 65 1.8k 0.4× 7.3k 2.2× 4.4k 1.8× 453 0.2× 2.4k 1.9× 324 15.0k
Clayton A. Smith United States 35 2.9k 0.6× 1.1k 0.3× 2.7k 1.1× 216 0.1× 1.1k 0.9× 129 5.5k
Tucker W. LeBien United States 45 2.1k 0.4× 1.3k 0.4× 2.1k 0.9× 161 0.1× 1.4k 1.1× 139 7.6k
Darren R. Veach United States 26 1.3k 0.3× 849 0.3× 1.5k 0.6× 543 0.3× 1.0k 0.8× 58 4.0k
W. Michael Kuehl United States 49 4.6k 1.0× 1.3k 0.4× 6.7k 2.8× 158 0.1× 2.5k 2.0× 99 9.6k
Kenneth A. Foon United States 44 1.5k 0.3× 3.2k 1.0× 2.3k 0.9× 220 0.1× 3.5k 2.9× 190 10.3k

Countries citing papers authored by Neil P. Shah

Since Specialization
Citations

This map shows the geographic impact of Neil P. Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil P. Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil P. Shah more than expected).

Fields of papers citing papers by Neil P. Shah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil P. Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil P. Shah. The network helps show where Neil P. Shah may publish in the future.

Co-authorship network of co-authors of Neil P. Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Neil P. Shah. A scholar is included among the top collaborators of Neil P. Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil P. Shah. Neil P. Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shah, Neil P., et al.. (2025). Resistance to Allosteric Inhibitors. PubMed. 437(20). 169133–169133. 1 indexed citations
2.
Ruiz, Diego Garrido, RosaAnna DeFilippis, Delphine Réa, et al.. (2024). BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood. 144(6). 639–645. 15 indexed citations
3.
Atallah, Ehab, Michael S. Broder, Onyee Chan, et al.. (2024). U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML). Blood. 144(Supplement 1). 5052–5052.
4.
Abramowitz, Steven, Hamid Mojibian, Nicolas J. Mouawad, et al.. (2024). Comparison of anticoagulation vs mechanical thrombectomy for the treatment of iliofemoral deep vein thrombosis. Journal of Vascular Surgery Venous and Lymphatic Disorders. 12(4). 101825–101825. 6 indexed citations
5.
6.
Smith, Catherine C., Aaron D. Viny, Evan Massi, et al.. (2021). Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical Cancer Research. 27(14). 4003–4011. 11 indexed citations
7.
Cortopassi, Wilian A., Diego Garrido Ruiz, Kibeom Jang, et al.. (2019). ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17–Mutant KIT. Cancer Research. 79(16). 4283–4292. 26 indexed citations
8.
Shah, Neil P., Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco, et al.. (2019). Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leukemia & lymphoma. 61(3). 650–659. 97 indexed citations
9.
Shah, Neil P., Antonio Jiménez‐Velasco, Sarah M. Larson, et al.. (2018). Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE). Clinical Lymphoma Myeloma & Leukemia. 18. S220–S221. 1 indexed citations
10.
Smith, Catherine C., Amy L. Paguirigan, Grace R. Jeschke, et al.. (2017). Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 130(1). 48–58. 120 indexed citations
11.
12.
Talpaz, Moshe, Jörge E. Cortes, Hagop M. Kantarjian, et al.. (2015). Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).. Journal of Clinical Oncology. 33(15_suppl). 7047–7047. 6 indexed citations
13.
Kesarwani, Meenu, Zachary Kincaid, Chris R. Evelyn, et al.. (2015). Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Scientific Reports. 5(1). 14538–14538. 43 indexed citations
14.
Chatterjee, Anindya, Joydeep Ghosh, Baskar Ramdas, et al.. (2014). Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Reports. 9(4). 1333–1348. 45 indexed citations
15.
Cortes, Jörge E., Giuseppe Saglio, Michele Baccarani, et al.. (2014). Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056). Blood. 124(21). 152–152. 59 indexed citations
16.
Lasater, Elisabeth A., Cheryl Tajon, Juan A. Osés-Prieto, et al.. (2013). MEK-Dependent Negative Feedback Underlies BCR–ABL-Mediated Oncogene Addiction. Cancer Discovery. 4(2). 200–215. 27 indexed citations
17.
Kantarjian, Hagop M. & Neil P. Shah. (2010). Drs. Kantarjian and Shah reply. New England Journal of Medicine. 363(17). 1674–1675. 1 indexed citations
18.
Seeliger, Markus A., Pratistha Ranjitkar, Corynn Kasap, et al.. (2009). Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations. Cancer Research. 69(6). 2384–2392. 127 indexed citations
19.
20.
Shah, Neil P., Owen N. Witte, & Christopher T. Denny. (1991). Characterization of the BCR Promoter in Philadelphia Chromosome-Positive and -Negative Cell Lines. Molecular and Cellular Biology. 11(4). 1854–1860. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José M. Trujillo Breakdown of academic impact, for papers by Maryalice Stetler‐Stevenson Breakdown of academic impact, for papers by Herbert Lazarus Breakdown of academic impact, for papers by Mariusz A. Wasik Breakdown of academic impact, for papers by Freda K. Stevenson Breakdown of academic impact, for papers by Clayton A. Smith Breakdown of academic impact, for papers by Tucker W. LeBien Breakdown of academic impact, for papers by Darren R. Veach Breakdown of academic impact, for papers by W. Michael Kuehl Breakdown of academic impact, for papers by Kenneth A. Foon
Rankless by CCL
2026